References
- Walton SE, Krotulski AJ, Logan BK. A forward-thinking approach to addressing the new synthetic opioid 2-benzylbenzimidazole nitazene analogs by liquid chromatography-tandem quadrupole mass spectrometry (LC-QQQ-MS). J Anal Toxicol. 2022;46(3):221–231. doi: 10.1093/jat/bkab117.
- Montanari E, Madeo G, Pichini S, et al. Acute intoxications and fatalities associated with benzimidazole opioid (nitazene analog) use: a systematic review. Ther Drug Monit. 2022;44(4):494–510. doi: 10.1097/ftd.0000000000000970.
- Pergolizzi J, Raffa R, LeQuang JAK, et al. Old drugs and new challenges: a narrative review of nitazenes. Cureus. 2023;15(6):e40736. doi: 10.7759/cureus.40736.
- Pucci M, Hudson S, Hill SL, et al. Severe toxicity involving N-pyrrolidino etonitazene in the United Kingdom-a case report. Clin Toxicol. 2022;60(4):533–534. doi: 10.1080/15563650.2021.1979235.
- Miskin S, Paduano M. Concerns at rise in suspected drugs deaths in Birmingham. BBC News. 2023 [cited 2023 Nov 10]. https://www.bbc.co.uk/news/uk-england-birmingham-66430596.
- CFSRE. New potent synthetic opioid- N-desethyl isotonitazene proliferating among recreational drug supply in USA. United States of America: The Center for Forensic Science Research & Education. 2023 [cited 2023 Sep 15]. https://www.drugsandalcohol.ie/38001/1/Public_Alert_N-Desethyl_Isotonitazene_232401AK.pdf.
- Malcolm NJ, Palkovic B, Sprague DJ, et al. Mu-opioid receptor selective superagonists produce prolonged respiratory depression. iScience. 2023;26(7):107121. doi: 10.1016/j.isci.2023.107121.
- HRB. A review of the evidence on the use and harms of 2-benzyl benzimidazole (“nitazene”) and piperidine benzimidazolone (‘brorphine-like’) opioids. July 2022 [cited 2023 November 10]. https://assets.publishing.service.gov.uk/media/63dd3485d3bf7f07038a5673/The_government_s_response_to_the_ACMD_s_advice_on_2-benzyl_benzimidazole_and_piperidine_benzimidazolone_opioids.pdf.
- Baumann MH, Glatfelter GC, Walther D, et al. Pharmacodynamics and pharmacokinetics of the non-fentanyl synthetic opioid, isotonitazene, in male rats. FASEB J. 2022;36(S1):R3857. doi: 10.1096/fasebj.2022.36.S1.R3857.
- Ball NS, Knable BM, Relich TA, et al. Xylazine poisoning: a systematic review. Clin Toxicol. 2022;60(8):892–901. doi: 10.1080/15563650.2022.2063135.
- Torruella RA. Xylazine (veterinary sedative) use in Puerto Rico. Subst Abuse Treat Prev Policy. 2011;6(1):7. doi: 10.1186/1747-597X-6-7.
- Ruiz-Colón K, Chavez-Arias C, Díaz-Alcalá JE, et al. Xylazine intoxication in humans and its importance as an emerging adulterant in abused drugs: a comprehensive review of the literature. Forensic Sci Int. 2014;240:1–8. doi: 10.1016/j.forsciint.2014.03.015.
- Rock KL, Lawson AJ, Duffy J, et al. The first drug-related death associated with xylazine use in the UK and Europe. J Forensic Leg Med. 2023;97:102542. doi: 10.1016/j.jflm.2023.102542.
- Johnson J, Pizzicato L, Johnson C, et al. Increasing presence of xylazine in heroin and/or fentanyl deaths, Philadelphia, Pennsylvania, 2010–2019. Inj Prev. 2021;27(4):395–398. doi: 10.1136/injuryprev-2020-043968.
- Mansfield D. Truly unprecedented: the Taliban drugs Ban v2.0. Alcis. 2023 [cited 2023 Nov 10]. https://www.alcis.org/post/taliban-drugs-ban.
- Love JS, Levine M, Aldy K, et al. Opioid overdoses involving xylazine in emergency department patients: a multicenter study. Clin Toxicol. 2023;61(3):173–180. doi: 10.1080/15563650.2022.2159427.
- De Baerdemaeker KSC, Dines AM, Hudson S, et al. Isotonitazene, a novel psychoactive substance opioid, detected in two cases following a local surge in opioid overdoses. QJM. 2023;116(2):115–119. doi: 10.1093/qjmed/hcac039.
- Krotulski AJ, Papsun DM, Kacinko SL, et al. Isotonitazene quantitation and metabolite discovery in authentic forensic casework. J Anal Toxicol. 2020;44(6):521–530. doi: 10.1093/jat/bkaa016.